StockData
Azitra, Inc. logo

Azitra, Inc. (AZTR) company profile

AZTRNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$0.61−0.02 (-3.03%)

Close on Nov 17, 2026Market cap $36.85MP/E –Yield –

About Azitra

Pharmaceutical Preparations, SIC 2834

Azitra, Inc. is an early-stage clinical biopharmaceutical company that develops innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company focuses on genetically engineering commensal skin bacteria, primarily Staphylococcus epidermidis, to deliver therapeutic proteins and living organisms into deeper skin layers. Its product candidate pipeline includes ATR-12 for treating Netherton syndrome, ATR-04 for papulopustular rash caused by epidermal growth factor receptor inhibitor cancer therapies, and ATR-01 for ichthyosis vulgaris. Azitra serves patients suffering from rare, chronic, and treatment-induced dermatologic conditions.

The company operates a proprietary microbial library containing approximately 1,500 unique bacterial strains and over 60 distinct bacterial species. Azitra has not commenced commercial operations and pursues partnerships and licensing agreements with academic and research institutions across the United States. Azitra was incorporated under Delaware law, and the provided text does not disclose its specific headquarters location.

Summary of the business section of Azitra's latest annual report, written by StockData.

Company profile

Company

Legal name
Azitra, Inc.
Founded
2014
Headquarters
Branford, CT
Address
21 Business Park Drive, Suite 6 06405
Phone
(203) 489-0183
Employees
13, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
GRASSI & CO., CPAs, P.C., Jericho, New York

Stock & identifiers

Ticker
AZTR
Exchange
NYSE
IPO date
Jun 21, 2023
Shares outstanding
61M, Aug 11, 2026
Public float
$4.70M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-6.67 reverse, Aug 21, 2025; 1-for-6.67 reverse, Aug 21, 2025; 1-for-30 reverse, Jul 1, 2024
SEC CIK
1701478
CUSIP
05479L302
ISIN
US05479L3024
FIGI
BBG00GDC73T8
Share class FIGI
BBG00GDC73V5
EIN
46-4478536

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Francisco D. SalvaPresident and CEO, Director4,086,291
Travis WhitfillChief Operating Officer, Director334,500
Norm StaskeyChief Financial Officer51,100
John R. SchroerDirector–
Barbara RyanDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Francisco Salva
Pres. and CEO
$450.00K$17.60K$115.50K$1.08K$584.18K+32%
Norman Staskey
CFO
–$3.84K–$493.64K$497.48K+9%
Travis Whitfill
COO
$396.00K$7.04K$88.35K$1.01K$492.40K+28%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 21, 2023
Offer price
$5.00
Securities offered
1,500,000
Gross proceeds
$7.50M
Exchange
NYSE American
First trading day
Jun 20, 2023
First-day close
$4.47-10.7%
Lock-up ends (est.)
Dec 17, 2023

“The initial public offering price of our shares is $5.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this report, we have 13 employees and full-time consultants, including our executive officers, providing management and financial services, and general administrative responsibilities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?